MediGene AG To Present At PIVAC Conference Rome
Martinsried/Munich, 25 September, 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) today presents at the 14th International Conference on Progress in Vaccination Against Cancer taking place from 24 - 26 September in Rome. The poster presentation entitled "Evaluation of a new generation dendritic cell-based vaccine for treatment of patients with castration-resistant prostate cancer" shows preclinical data on Medigene's immunotherapeutic DC vaccine program. The abstract is available for download on Medigene's company website at http://www.medigene.com/products-pipeline/development-projects/immunotherapies/abstracts.
About Medigene's DC vaccines: The platform for the development of antigen-tailored DC vaccines is the most advanced platform of the three highly innovative and complementary immunotherapy platforms of Trianta Immunotherapies, which was recently acquired by Medigene AG. Currently the DC vaccines are being evaluated in two ongoing investigator-initiated trials in clinical phases II (prostate cancer) and I/II (AML, acute myeloid leukaemia). Medigene concentrates on the further development of DC vaccines in hematological malignancies and plans to initiate a further clinical study in AML in 2014.
Medigene's dendritic cell product platform allows the design of new generation dendritic cell vaccines. Dendritic cells can take up antigens efficiently, process them and present them on their surface in a form that can induce T cells to divide and mature. Dendritic cells can also induce natural killer cells to become active and attack tumour cells. Medigene/Trianta has established new, fast and efficient methods for preparation of autologous (patient-specific) mature dendritic cells that have relevant characteristics to activate both T cells and natural killer cells. They are developed to carry multiple tumour antigens to treat various types of cancer, suited for treatment of minimal residual disease or use in combination therapies.
About PIVAC: Progress in Vaccination Against Cancer (PIVAC) aims to bring together translational and clinical oncologists and immunologists dealing with active vaccination against cancer for three days of presentations on the most recent advances in the field. Besides providing an up-to-date overview of many aspects of tumour immunology, PIVAC fosters a lively and fruitful discussion, promoting interactions between participants, speakers and companies attending the conference and encouraging the emergence of new partnerships. More information at: http://www.eacr.org/pivac14/index.php
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Help employers find you! Check out all the jobs and post your resume.